SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii

Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rif...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurawski, Daniel V., Reinhart, Alexandria A., Alamneh, Yonas A., Pucci, Michael J., Si, Yuanzheng, Abu-Taleb, Rania, Shearer, Jonathan P., Demons, Samandra T., Tyner, Stuart D., Lister, Troy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700309/
https://www.ncbi.nlm.nih.gov/pubmed/28947471
http://dx.doi.org/10.1128/AAC.01239-17
_version_ 1783281105854529536
author Zurawski, Daniel V.
Reinhart, Alexandria A.
Alamneh, Yonas A.
Pucci, Michael J.
Si, Yuanzheng
Abu-Taleb, Rania
Shearer, Jonathan P.
Demons, Samandra T.
Tyner, Stuart D.
Lister, Troy
author_facet Zurawski, Daniel V.
Reinhart, Alexandria A.
Alamneh, Yonas A.
Pucci, Michael J.
Si, Yuanzheng
Abu-Taleb, Rania
Shearer, Jonathan P.
Demons, Samandra T.
Tyner, Stuart D.
Lister, Troy
author_sort Zurawski, Daniel V.
collection PubMed
description Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR) A. baumannii strain. In standard in vitro assays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection.
format Online
Article
Text
id pubmed-5700309
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-57003092017-12-01 SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii Zurawski, Daniel V. Reinhart, Alexandria A. Alamneh, Yonas A. Pucci, Michael J. Si, Yuanzheng Abu-Taleb, Rania Shearer, Jonathan P. Demons, Samandra T. Tyner, Stuart D. Lister, Troy Antimicrob Agents Chemother Experimental Therapeutics Acinetobacter baumannii is responsible for 10% of all nosocomial infections and has >50% mortality rates when causing ventilator-associated pneumonia. In this proof-of-concept study, we evaluated SPR741, an antibiotic adjuvant that permeabilizes the Gram-negative membrane, in combination with rifampin against AB5075, an extensively drug-resistant (XDR) A. baumannii strain. In standard in vitro assays and in a murine pulmonary model, we found that this drug combination can significantly reduce bacterial burden and promote animal survival despite an aggressive infection. American Society for Microbiology 2017-11-22 /pmc/articles/PMC5700309/ /pubmed/28947471 http://dx.doi.org/10.1128/AAC.01239-17 Text en Copyright © 2017 Zurawski et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Experimental Therapeutics
Zurawski, Daniel V.
Reinhart, Alexandria A.
Alamneh, Yonas A.
Pucci, Michael J.
Si, Yuanzheng
Abu-Taleb, Rania
Shearer, Jonathan P.
Demons, Samandra T.
Tyner, Stuart D.
Lister, Troy
SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
title SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
title_full SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
title_fullStr SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
title_full_unstemmed SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
title_short SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii
title_sort spr741, an antibiotic adjuvant, potentiates the in vitro and in vivo activity of rifampin against clinically relevant extensively drug-resistant acinetobacter baumannii
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700309/
https://www.ncbi.nlm.nih.gov/pubmed/28947471
http://dx.doi.org/10.1128/AAC.01239-17
work_keys_str_mv AT zurawskidanielv spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT reinhartalexandriaa spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT alamnehyonasa spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT puccimichaelj spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT siyuanzheng spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT abutalebrania spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT shearerjonathanp spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT demonssamandrat spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT tynerstuartd spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii
AT listertroy spr741anantibioticadjuvantpotentiatestheinvitroandinvivoactivityofrifampinagainstclinicallyrelevantextensivelydrugresistantacinetobacterbaumannii

Ejemplares similares